Gene therapy for cystic fibrosis: 15-Year safety watch begins
NCT ID NCT06962852
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 5 people with cystic fibrosis who previously received a single dose of BI 3720931 gene therapy or placebo. No new treatment is given. Researchers will monitor participants for up to 15 years to check for long-term side effects and track lung function. The goal is to understand the lasting safety and effectiveness of this gene therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hôpital Gui de Chauliac
Montpellier, 34295, France
-
Osp. Pediatrico Bambin Gesù
Roma, 00165, Italy
-
Royal Brompton Hospital
London, SW3 6JY, United Kingdom
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- Can a peer coach help young people take control of their chronic illness?
- Could a single antibiotic be enough for cystic fibrosis lung infections?
- Early use of powerful CF drugs may boost growth in young children
- Hands-On therapy may soothe cystic fibrosis pain without drugs